Pathological significance and predictive value for biochemical recurrence of c-Fes expression in prostate cancer

Prostate

Volumn 72, Issue 2, 2012, Pages 201-208

  Miyata, Yasuyoshi ^a,d   Watanabe, Shin Ichi ^a   Matsuo, Tomohiro ^a   Hayashi, Tomayoshi ^b   Sakai, Hideki ^a   Xuan, Jim W ^c   Greer, Peter A ^d   Kanda, Shigeru ^e  

^a NAGASAKI UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

^e NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

animal model; biomarker; c Fes; prostate cancer; recurrence

Indexed keywords

PROTEIN KINASE FES;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MOUSE; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE CANCER BIOCHEMICAL RECURRENCE; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MICE; MICE, TRANSGENIC; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-FES; RETROSPECTIVE STUDIES;

EID: 84455161362     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21422     Document Type: Article

References (33)

1. Greer P,. Closing in on the biological functions of Fps/Fes and Fer. Nat Rev Mol Cell Biol 2002; 3: 278-289. (Pubitemid 34619263)
2. Sherr CJ, Fedele LA, Oskarsson M, Maizel J, Woude GV,. Molecular cloning of Snyder-Theilen feline leukemia and sarcoma viruses: Comparative studies of feline sarcoma virus with its natural helper virus and with Moloney murine sarcoma virus. J Virol 1980; 34: 200-212. (Pubitemid 10149396)
3. Shibuya M, Hanafusa T, Hanafusa H, Stephenson JR,. Homology exists among the transforming sequences of avian and feline sarcoma viruses. Proc Natl Acad Sci U S A 1980; 77: 6536-6540. (Pubitemid 11219163)
4. Haigh J, McVeigh J, Greer P,. The fps/fes tyrosine kinase is expressed in myeloid, vascular endothelial, epithelial, and neuronal cells and is localized in the trans-golgi network. Cell Growth Differ 1996; 7: 931-944. (Pubitemid 26360733)
5. Truesdell PF, Zirngibl RA, Francis S, Sangrar W, Greer PA,. fps/fes knockout mice display a lactation defect and the fps/fes tyrosine kinase is a component of E-cadherin-based adherens junctions in breast epithelial cells during lactation. Exp Cell Res 2009; 315: 2929-2940.
6. MacDonald I, Levy J, Pawson T,. Expression of the mammalian c-fes protein in hematopoietic cells and identification of a distinct fes-related protein. Mol Cell Biol 1985; 5: 2543-2551. (Pubitemid 15249538)
7. Kanda S, Kanetake H, Miyata Y,. Downregulation of Fes inhibits VEGF-A-induced chemotaxis and capillary-like morphogenesis by cultured endothelial cells. J Cell Mol Med 2007; 11: 495-501. (Pubitemid 47153459)
8. Kanda S, Mochizuki Y, Miyata Y, Kanetake H,. The role of c-Fes in vascular endothelial growth factor-A-mediated signaling by endothelial cells. Biochem Biophys Res Commun 2003; 306: 1056-1063. (Pubitemid 36776238)
9. Parsons SA, Greer PA,. The Fps/Fes kinase regulates the inflammatory response to endotoxin through down-regulation of TLR4, NF-kappaB activation, and TNF-alpha secretion in macrophages. J Leukoc Biol 2006; 80: 1522-1528. (Pubitemid 44904991)
10. Parsons SA, Mewburn JD, Truesdell P, Greer PA,. The Fps/Fes kinase regulates leucocyte recruitment and extravasation during inflammation. Immunology 2007; 122: 542-550. (Pubitemid 350075950)
11. Yee SP, Mock D, Greer P, Maltvy V, Rossant J, Bernstein A, Pawson T,. Lymphoid and mesenchymal tumors in transgenic mice expressing the v-fps protein-tyrosine kinase. Mol Cell Biol 1989; 9: 5491-5499. (Pubitemid 20004367)
12. Delfino FJ, Stevenson H, Smithgall TE,. A growth-suppressive function for the c-fes protein-tyrosine kinase in colorectal cancer. J Biol Chem 2006; 281: 8829-8835. (Pubitemid 43847989)
13. Yu G, Smithgall TE, Glazer RI,. K562 leukemia cells transfected with the human c-fes gene acquire the ability to undergo myeloid differentiation. J Biol Chem 1989; 264: 10276-10281. (Pubitemid 19159301)
14. Sangrar W, Zirgnibl RA, Gao Y, Muller WJ, Jia Z, Greer PA,. An identity crisis for fps/fes: Oncogene or tumor suppressor? Cancer Res 2005; 65: 3518-3522. (Pubitemid 40616322)
15. Slamon DJ, deKernion JB, Verma IM, Cline MJ,. Expression of cellular oncogenes in human malignancies. Science 1984; 224: 256-262. (Pubitemid 14172510)
16. Kacinski BM, Carter D, Kohorn EI, Mittal K, Bloodgood RS, Donahue J, Kramer CA, Fisher D, Edwards R, Chambers SK, Chanbers JT, Schwartz PE,. Oncogene expression in vivo by ovarian adenocarcinomas and mixed-mullerian tumors. Yale J Biol Med 1989; 62: 379-392. (Pubitemid 20005030)
17. Karthaus HF, Schalken JA, Feitz WF, Debruyne FM, De Haan PT, Bloemers HP, van den Ven WJ,. Expression of the human fes cellular oncogene in renal cell tumors. Urol Res 1986; 14: 123-127. (Pubitemid 16090996)
18. Smithgall TE, Johnston JB, Bustin M, Glazer RI,. Elevated expression of the c-fes proto-oncogene in adult human myeloid leukemia cells in the absence of gene amplification. J Natl Cancer Inst 1991; 83: 42-46.
19. Bouchardy C, Fioretta G, Rapiti E, Verkooijen HM, Rapin CH, Schmidlin F, Miralbell R, Zanetti R,. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer 2008; 123: 421-429. (Pubitemid 351842029)
20. van Leeuwen PJ, van Vugt HA, Bangma CH,. The implementation of screening for prostate cancer. Prostate Cancer Prostatic Dis 2010; 13: 218-227.
21. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP,. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009; 41: 619-624.
22. King JC, Xu J, Wongvipat J, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, Gerald WL, Sawyers CL,. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009; 41: 524-526.
23. Alimonti A, Nardella C, Chen Z, Tessier S, Tanguay S, Chevrette M, Aprikan A, Chevalier S,. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest 2010; 120: 681-693.
24. Macfarlane RJ, Chi KN,. Novel targeted therapies for prostate cancer. Urol Clin North Am 2010; 37: 105-119.
25. Duan W, Gabril MY, Moussa M, Chan FL, Sakai H, Fong G, Xuan FJ,. Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model. Oncogene 2005; 24: 1510-1524. (Pubitemid 40396081)
26. Gabril MY, Duan W, Wu G, Moussa M, Izawa JI, Panchal CI, Sakai H, Xuan JW,. A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies. Mol Ther 2005; 11: 348-362. (Pubitemid 40277311)
27. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-1242. (Pubitemid 41232997)
28. Zirngibl RA, Senis Y, Greer PA,. Enhanced endotoxin sensitivity in fps/fes-null mice with minimal defects in hematopoietic homeostasis. Mol Cell Biol 2002; 22: 2472-2486. (Pubitemid 34262970)
29. Ohba K, Miyata Y, Watanabe S, Hayashi T, Kanetake H, Kanda S, Sakai H,. Clinical significance and predictive value of prostaglandin e2 receptors (EPR) 1-4 in patients with renal cell carcinoma. Anticancer Res 2011; 31: 597-605.
30. Deutsch EW, Ball CA, Berman JJ, Bova GS, Brazma A, Bumgarner RE, Campbell D, Causton HC, Christiansen JH, Daian F, Dauga D, Davidson DR, Gimenez G, Goo YA, Grimmond S, Henrich T, Herrmann BG, Johnson MH, Korb M, Mills JC, Oudes AJ, Parkinson HE, Pascal LE, Pollet N, Quackenbush J, Ramialison M, Ringwald M, Salgado D, Sansone SA, Sherlock G, Stoeckert CJ Jr, Swedlow J, Taylor RC, Walashek L, Warford A, Wilkinson DG, Zhou Y, Zon LI, Liu AY, True LD,. Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE). Nat Biotechnol 2008; 26: 305-312. (Pubitemid 351355130)
31. Bordeaux J, Welsh A, Agarwal S, Killiam E, Baquero M, Hanna J, Anagnostou V, Rimm D,. Antibody validation. Biotechniques 2010; 48: 197-209.
32. Kanda S, Miyata Y, Kanetake H, Smithgall TE,. Downregulation of the c-Fes protein-tyrosine kinase inhibits the proliferation of human renal carcinoma cells. Int J Oncol 2009; 34: 89-96.
33. Zoubeidi A, Rocha J, Zouanat FZ, Hamel L, Scarlata E, Aprikian AG, Chevalier S,. The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth. Mol Cancer Res 2009; 7: 142-155.